3,4-difluoro-N-{1-[(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)methyl]piperidin-4-yl}benzamide | 1220639-33-7

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: 3,4-difluoro-N-{1-[(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)methyl]piperidin-4-yl}benzamide
• 英文别名: 3,4-difluoro-N-[1-[(2-oxo-3,4-dihydro-1H-quinolin-7-yl)methyl]piperidin-4-yl]benzamide
• CAS: 1220639-33-7
• 化学式: C₂₂H₂₃F₂N₃O₂
• 分子量: 399.44
• InChiKey: CHETVKYCDXXDLG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  61.4
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• [EN] 7-PIPERIDINOALKYL-3,4-DIHYDROQUINOLONE DERIVATIVE<br/>[FR] DÉRIVÉ DE 7-PIPÉRIDINOALKYLE-3,4-DIHYDROQUINOLONE
  申请人：TAISHO PHARMA CO LTD

  公开号：WO2010038901A1

  公开（公告）日：2010-04-08

  To provide a novel compound, a pharmaceutically acceptable salt or a hydrate thereof useful for preventing or treating for depression, anxiety disorders (such as generalized anxiety disorder, posttraumatic stress disorder, panic disorder, obsessive-compulsive disorder or social anxiety disorder), attention deficit disorder, mania, manic-depressive illness, schizophrenia, mood disorders, stress, sleep disorders, attacks, memory impairment, cognitive impairment, dementia, amnesia, delirium, obesity, eating disorder, appetite disorder, hyperphagia, bulimia, cibophobia, diabetes, cardiovascular diseases, hypertension, dyslipidemia, myocardial infarction, movement disorder (such as Parkinson's disease, epilepsy, convulsion or tremor), drug abuse, drug addiction or sexual dysfunction, based on a melanin-concentrating hormone receptor (MCH receptor) antagonistic action. SOLUTION A compound, a pharmaceutically acceptable salt or a hydrate thereof represented by the formula (I).

  为了提供一种新型化合物、药用可接受的盐或其水合物，用于预防或治疗抑郁症、焦虑障碍（如广泛性焦虑障碍、创伤后应激障碍、恐慌障碍、强迫症或社交焦虑障碍）、注意力缺陷障碍、狂躁症、躁郁病、精神分裂症、情绪障碍、压力、睡眠障碍、发作、记忆障碍、认知障碍、痴呆、健忘症、谵妄、肥胖、进食障碍、食欲障碍、暴饮暴食、贪食症、厌食症、糖尿病、心血管疾病、高血压、血脂异常、心肌梗死、运动障碍（如帕金森病、癫痫、抽搐或震颤）、药物滥用、药物成瘾或性功能障碍，基于黑色素浓集素受体（MCH受体）的拮抗作用。解决方案是一种化合物，药用可接受的盐或其水合物，其化学式表示为（I）。
• 7-PIPERIDINOALKYL-3, 4-DIHYDROQUINOLONE DERIVATIVE
  申请人：Kanuma Kosuke

  公开号：US20110178304A1

  公开（公告）日：2011-07-21

  Problem To provide a novel compound, a pharmaceutically acceptable salt or a hydrate thereof useful for preventing or treating for depression, anxiety disorders (such as generalized anxiety disorder, posttraumatic stress disorder, panic disorder, obsessive-compulsive disorder or social anxiety disorder), attention deficit disorder, mania, manic-depressive illness, schizophrenia, mood disorders, stress, sleep disorders, attacks, memory impairment, cognitive impairment, dementia, amnesia, delirium, obesity, eating disorder, appetite disorder, hyperphagia, bulimia, cibophobia, diabetes, cardiovascular diseases, hypertension, dyslipidemia, myocardial infarction, movement disorder (such as Parkinson's disease, epilepsy, convulsion or tremor), drug abuse, drug addiction or sexual dysfunction, based on a melanin-concentrating hormone receptor (MCH receptor) antagonistic action. Solution A compound, a pharmaceutically acceptable salt or a hydrate thereof represented by the formula (I).

  问题：提供一种新化合物、药用可接受的盐或其水合物，用于预防或治疗抑郁症、焦虑症（如广泛性焦虑症、创伤后应激障碍、恐慌症、强迫症或社交焦虑症）、注意力缺陷障碍、躁狂、躁郁病、精神分裂症、情绪障碍、压力、睡眠障碍、发作、记忆障碍、认知障碍、痴呆、健忘症、谵妄、肥胖症、进食障碍、食欲障碍、暴食症、食物恐惧症、糖尿病、心血管疾病、高血压、血脂异常、心肌梗塞、运动障碍（如帕金森病、癫痫、惊厥或震颤）、药物滥用、药物成瘾或性功能障碍，基于黑色素浓集激素受体（MCH受体）拮抗作用。 解决方案：一种化合物、药用可接受的盐或其水合物，其化学式为（I）。
• 7-PIPERIDINOALKYL-3,4-DIHYDROQUINOLONE DERIVATIVE
  申请人：Taisho Pharmaceutical Co., Ltd.

  公开号：EP2344471A1

  公开（公告）日：2011-07-20
• US8461182B2
  申请人：——

  公开号：US8461182B2

  公开（公告）日：2013-06-11